- Home
- Medical news & Guidelines
- Anesthesiology
- Cardiology and CTVS
- Critical Care
- Dentistry
- Dermatology
- Diabetes and Endocrinology
- ENT
- Gastroenterology
- Medicine
- Nephrology
- Neurology
- Obstretics-Gynaecology
- Oncology
- Ophthalmology
- Orthopaedics
- Pediatrics-Neonatology
- Psychiatry
- Pulmonology
- Radiology
- Surgery
- Urology
- Laboratory Medicine
- Diet
- Nursing
- Paramedical
- Physiotherapy
- Health news
- Fact Check
- Bone Health Fact Check
- Brain Health Fact Check
- Cancer Related Fact Check
- Child Care Fact Check
- Dental and oral health fact check
- Diabetes and metabolic health fact check
- Diet and Nutrition Fact Check
- Eye and ENT Care Fact Check
- Fitness fact check
- Gut health fact check
- Heart health fact check
- Kidney health fact check
- Medical education fact check
- Men's health fact check
- Respiratory fact check
- Skin and hair care fact check
- Vaccine and Immunization fact check
- Women's health fact check
- AYUSH
- State News
- Andaman and Nicobar Islands
- Andhra Pradesh
- Arunachal Pradesh
- Assam
- Bihar
- Chandigarh
- Chattisgarh
- Dadra and Nagar Haveli
- Daman and Diu
- Delhi
- Goa
- Gujarat
- Haryana
- Himachal Pradesh
- Jammu & Kashmir
- Jharkhand
- Karnataka
- Kerala
- Ladakh
- Lakshadweep
- Madhya Pradesh
- Maharashtra
- Manipur
- Meghalaya
- Mizoram
- Nagaland
- Odisha
- Puducherry
- Punjab
- Rajasthan
- Sikkim
- Tamil Nadu
- Telangana
- Tripura
- Uttar Pradesh
- Uttrakhand
- West Bengal
- Medical Education
- Industry
Novo Holdings to acquire majority stake in Single Use Support
Denmark: Novo Holdings A/S has announced that it has agreed to acquire a majority stake in Single Use Support, a fast-growing life science tools company providing advanced technology solutions for the pharmaceutical production process.
Novo Holdings will acquire an approximately 60% controlling stake, alongside the two company founders who will each retain 10% and Danaher which will retain 20% of the share capital.
Founded in 2017 in Kufstein, Austria by Johannes Kirchmair and Thomas Wurm, Single Use Support is at the forefront of transforming the production process for advanced pharmaceutical modalities with its equipment and consumables used in the bioprocessing value chain. With a focus on solutions for biological drug substances, cell and gene therapies, and mRNA vaccines, the company's customers include leading pharma companies, biotech companies and CDMOs.
Single Use Support's products have rapidly gained widespread adoption by enhancing operational efficiency, minimising leakage, and effectively mitigating contamination risks in the pharmaceutical production process.
Johan Hueffer, Senior Partner, Principal Investments, Novo Holdings, said: "We are pleased to announce the acquisition of a majority stake in Single Use Support, a leading provider of advanced fluid management solutions. This transaction marks an important and complimentary addition to our fast-growing life science tools & diagnostics portfolio and represents our first control investment in the DACH region, a vital hub for life sciences. This investment also underscores our commitment to advancing leading healthcare therapies and technologies."
Tuomas Toiviainen, Partner, Principal Investments, Novo Holdings, added, "We are excited to partner with existing shareholders and management to support the next phase of growth and drive further innovation in the rapidly expanding bioprocessing market. This acquisition demonstrates our expertise and investment focus in backing high-quality life science tools companies. We look forward to working with the Single Use Support management team and employees who share our passion for innovation in the life science space."
Johannes Kirchmair and Thomas Wurm, founders of Single Use Support and board members, said, "Welcoming Novo Holdings as a partner marks a significant milestone in our growth journey at Single Use Support. We take pride in having nurtured and developed our company into a key player in the life sciences sector. As we embark on this new chapter, we are enthusiastic about the prospects of partnering with Novo Holdings, a global leader in life science investments. The collaboration aligns perfectly with our mission and complements our existing partnership with Danaher, which will continue as a valued partner. Together, we look forward to advancing our impact and innovation in the life sciences industry."
Chris Riley, Executive Vice President, Biotechnology Group, Danaher, said, "We are pleased to continue our involvement in Single Use Support and to partner with Novo Holdings as we take the company to the next level. At Danaher, we are focused on leveraging the power of science and technology to meaningfully improve human health, which makes Novo Holdings a very good long-term partner for us in the collaboration at Single Use Support and beyond."
Christian Praxmarer, CEO, Single Use Support, said, "Novo Holdings is joining us at a crucial moment as we prepare to further strengthen our global footprint, focusing on markets outside of Europe such as the US and Asia, and to engage with new customers. With significant insights into the life science tools sector and a comprehensive industry network, I am excited to work alongside Novo Holdings and make new strides in our shared mission of bringing better treatments to patients."
The transaction is subject to regulatory approvals. Kromann Reumert, DORDA, Linklaters and Wilson Sonsini served as legal advisors and William Blair served as financial advisor to Novo Holdings. E+H served as legal advisor while Jefferies LLC served as financial advisor to Single Use Support.
Read also: Novo Nordisk parent invests in India's Manipal hospital chain
Ruchika Sharma joined Medical Dialogue as an Correspondent for the Business Section in 2019. She covers all the updates in the Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She has completed her B.Com from Delhi University and then pursued postgraduation in M.Com. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751